What is XLO's P/E ratio?

XILIO DEVELOPMENT INC (XLO) currently trades at a P/E ratio of 5.76.

XILIO DEVELOPMENT INC reports a Return on Equity (ROE) of -43.15%.

What is XLO's dividend yield?

XILIO DEVELOPMENT INC offers a dividend yield of 0.00%.

What is XLO's Quality Score?

Our AI rates XLO's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy XLO?

Our AI Timing Score for XLO is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does XLO belong to?

XILIO DEVELOPMENT INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

XLO (NASDAQ) Stock Analysis | XILIO DEVELOPMENT INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

XLO AI Analysis Summary

Our AI summary for XLO: XILIO DEVELOPMENT INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 5.76, ROE of -43.15%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

XLO

XILIO DEVELOPMENT INC

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 9.11

0.03 (0.33%) Day Change

Watchlist Portfolio Compare Chart

5.76

P/E

0.02

D/E

-43.2%

ROE

-19.2%

ROA

0.00%

Div Yield

0.02

PEG

XILIO DEVELOPMENT INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 9.11 Price 0.03 (0.33%) Day Change	NEWS SCORE: N/A

XLO, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	9.11
PBV / Sector	0.82 / 5.20 GREAT
Earning Per Share	-4.78

PE / Sector	5.76 / 19.97 GREAT
PEG or PE/Growth / Sector	0.02 / 1.22 GREAT
Average 1M Daily Value	0.44 M GREAT
Average 1W Daily Value	0.21 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-58.52 / 98.71
NPM Average (%) / Sector	-352.21 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-19.15 / 27.02
ROA Average (%) / Sector	-62.37 / -368.17
ROA Change Average (%) / Sector	-5.64 / 5,404.12
ROE (%) / Sector	-43.15 / 3.47
ROE Average (%) / Sector	-152.70 / 6.51
ROE Change Average (%) / Sector	21.01 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:43
Symbol	XLO
Name	XILIO DEVELOPMENT INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	6.58 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	59.70 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 828 Winter Street, Waltham, MA, United States, 02451

Phone: 857 524 2466

Website: https://xiliotx.com

Employees: 76

Sector: Healthcare >> Biotechnology

Description: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.